ScreenNJ Annual Conference 2020 – Session 2

Understanding What’s New About Lung Cancer Screening &
Integrating Smoking Cessation Into Community Education and Primary Care Practice Effectively

Thursday, June 25, 2020
2:00 PM – 3:00 PM

CME/CE Certified Live Activity Provided by
Cancer Health Equity and Engagement
Rutgers Cancer Institute of New Jersey

Overview

This course is designed to provide participants with an understanding of: the guidelines, criteria, and current recommendations for and need for lung cancer screening and tobacco cessation services in NJ; the individual, organizational, and system-level barriers to lung cancer screening and specific educational and process improvement strategies to address these barriers and improving knowledge of, referral to, navigation through, and completion of lung cancer screening; implementation strategies (including eligibility assessment, screening completion, community engagement and education, and technology interventions) for improving lung cancer screening rates in safety net settings (including discussion of insurance coverages and best practices for guiding patients through insurance for this screening); and how to conduct education, patient assessment, and patient referral to tobacco cessation services (including best practices and what not to do when assisting tobacco-dependent patients).


Target Audience

This activity is designed for physicians, nurses, other healthcare providers and staff, health educators, community health workers, public health professionals, and other professionals who perform, refer to, and navigate patients and community members to cancer prevention and cancer screening services.


Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the basic epidemiology of tobacco use and lung cancer in NJ, including the leading causes/risks for lung cancer
  • Recognize how to conduct tobacco use assessment and patient referral to tobacco cessation services using best practices
  • Describe the guidelines, criteria, and current recommendations for lung cancer screening in NJ
  • Describe the individual, organizational, and system-level barriers to lung cancer screening
  • Recognize educational and process improvement strategies to address barriers to lung cancer screening to improve lung cancer screening rates


Faculty

Michael B. Steinberg, MD, MPH

Professor, Chief, Division of General Internal Medicine, Vice-Chair for Research, Department of Medicine, Rutgers Robert Wood Johnson Medical School; Director, Rutgers Tobacco Dependence Program/Center for Tobacco Studies, Rutgers School of Public Health Read full bio

Heather Jordan, MPH, CPH, MCHES

Research Program Manager, Division of General Internal Medicine, Department of Medicine, Rutgers Robert Wood Johnson Medical School Rutgers University School of Public Health Read full bio


Accreditation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:  Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses:  This activity is awarded 1 contact hour. (60-minute CH).  Nurses should only claim those contact hours actually spent participating in the activity.

An application has been submitted to award Certified Health Specialists (CHES) and Master Certified Health Education Specialists (MCHES) up to 1.0 total Category I Continuing Education Contact Hours (CECH).  Maximum Advanced-level contact hours available are 1.0. The Rutgers Center for Public Health Workforce Development is a designated multiple event provider of CECHs by the National Commission for Health Education Credentialing.

An application is pending for 1.0 NJ Public Health Continuing Education continuing education credits. Rutgers School of Public Health has been approved by the New Jersey Department of Health as a provider of New Jersey Public Health Continuing Education Contact Hours (CEs).


Method of Participation

In order to meet the learning objectives and receive continuing education credits, participants must watch the program in its entirety and complete the program evaluation.  A letter certifying attendance and credit verification will be emailed to participants approximately 30 days after completion of the online evaluation.


Peer Review

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences (RBHS) has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers.  This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by:

  • Rita Musanti, RN, PhD, Assistant Director of Community Outreach and Engagement, Rutgers Cancer Institute of New Jersey
  • Jeanne Ferrante, MD, MPH, Director, New Jersey Primary Care Research Network, Rutgers Robert Wood Johnson Medical School


Disclosure Declarations

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.


Faculty

  • Michael B. Steinberg, MD, MPH has no relevant financial relationships to disclose.
  • Heather Jordan, MPH, CPH, MCHES has no relevant financial relationships to disclose.

 

Peer Reviewers

  • Rita Musanti, RN, PhD, has no relevant financial relationships to disclose.
  • Jeanne Ferrante, MD, MPH, has no relevant financial relationships to disclose


Planners

Rutgers Biomedical and Health Sciences

  • Mary O’Dowd, MPH, Executive Director, Health Systems and Population Health Integration, has no relevant financial relationships to disclose.

Rutgers Cancer Institute of New Jersey

  • Rita Musanti, RN, PhD, Assistant Director of Community Outreach and Engagement, has no relevant financial relationships to disclose.
  • Emily Carey PerezdeAlejo, BS, REHS, ScreenNJ Program Manager, has no relevant financial relationships to disclose.
  • Isabelle Alexander, BA, ScreenNJ Staff Assistant, has no relevant financial relationships to disclose.

Rutgers Robert Wood Johnson Medical School

  • Nicolette Garthe, BS, Intern, Tobacco Dependence Program, has no relevant financial relationships to disclose.
  • Heather Jordan, MPH, CPH, MCHES, Research Program Manager, Tobacco Dependence Program, Division of General Internal Medicine, Department of Medicine, has no relevant financial relationships to disclose.
  • Jeanne Ferrante, MD, MPH, Director, New Jersey Primary Care Research Network, has no relevant financial relationships to disclose.

Rutgers Biomedical and Health Sciences Center for Continuing and Outreach Education

  • Patrick Dwyer, Director, Continuing Medical Education, has no relevant financial relationships to disclose.


Off-Label/Investigational Use

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation.  These disclosures will be made to the audience at the time of the activity.


Disclaimer

The views expressed in this activity are those of the faculty.  It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, or Rutgers.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate.  However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

RBHS reserves the right to modify the activity content and faculty if necessary.

Copyright © 2020. Rutgers Biomedical and Health Sciences. All rights reserved including translation into other languages.  No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers.

For questions or concerns regarding this activity, please contact the ScreenNJ Program / Cancer Health Equity and Engagement at screennj@cinj.rutgers.edu